Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anlotinib Dihydrochloride in Soft Tissue Sarcoma: NCT06506838 Clinical Landscape Report 2026
16 October 2026
NCT06506838 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oncolytic vaccinia virus (Hangzhou Gongchu Biotechnology) in Hepatocellular Carcinoma: NCT06508307 Clinical Landscape Report 2026
16 October 2026
NCT06508307 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IM19 CAR-T (Imunopharm) in Systemic Lupus Erythematosus: NCT06513429 Clinical Landscape Report 2026
16 October 2026
NCT06513429 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAR-T cell(The First Affiliated Hospital of Zhengzhou University) in Liver Cancer: NCT06515626 Clinical Landscape Report 2026
16 October 2026
NCT06515626 clinical landscape for Liver Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cetrelimab in Muscle Invasive Bladder Carcinoma: NCT06511648 Clinical Landscape Report 2026
16 October 2026
NCT06511648 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
CTIM-76 in Endometrial Carcinoma: NCT06515613 Clinical Landscape Report 2026
16 October 2026
NCT06515613 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NKX-019 in Systemic Lupus Erythematosus: NCT06518668 Clinical Landscape Report 2026
16 October 2026
NCT06518668 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitoxantrone Hydrochloride in Refractory Soft Tissue Sarcoma: NCT06514313 Clinical Landscape Report 2026
16 October 2026
NCT06514313 clinical landscape for Refractory Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trabectedin in Uterine Leiomyosarcoma: NCT06524583 Clinical Landscape Report 2026
16 October 2026
NCT06524583 clinical landscape for Uterine Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tuvusertib in Recurrent Endometrial Cancer: NCT06518564 Clinical Landscape Report 2026
16 October 2026
NCT06518564 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Recurrent Endometrial Cancer: NCT06522828 Clinical Landscape Report 2026
16 October 2026
NCT06522828 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Uveal Melanoma: NCT06519266 Clinical Landscape Report 2026
16 October 2026
NCT06519266 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.